Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors

Computational and Mathematical Methods in Medicine

Volumn 2014, Issue , 2014, Pages

  Qi, Yun Feng ^a   Huang, Yan Xin ^a   Dong, Yan ^a   Zheng, Li Hua ^a   Bao, Yong Li ^a   Sun, Lu Guo ^a   Wu, Yin ^a   Yu, Chun Lei ^a   Jiang, Hong Yu ^b   Li, Yu Xin ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLATION; CELL DEATH; GENE EXPRESSION; TIME SERIES; TUMORS;

DNA DAMAGE RESPONSE; GENE EXPRESSION TIME SERIES; HISTONE DEACETYLASES; MICROARRAY EXPERIMENTS; SUBEROYLANILIDE HYDROXAMIC ACIDS; TIME-SERIES GENE EXPRESSION DATA; TRANSCRIPTIONAL RESPONSE; US FOOD AND DRUG ADMINISTRATION;

TIME SERIES ANALYSIS;

HISTONE DEACETYLASE; PROTEIN P53; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MITOCHONDRION; TUMOR CELL; ALGORITHM; CLUSTER ANALYSIS; COMPUTER PROGRAM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; NEOPLASMS; PATHOLOGY; TIME;

ALGORITHMS; APOPTOSIS; CELL CYCLE; CLUSTER ANALYSIS; DNA DAMAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NEOPLASMS; SOFTWARE; TIME FACTORS;

EID: 84908335439     PISSN: 1748670X     EISSN: 17486718     Source Type: Journal    
DOI: 10.1155/2014/867289     Document Type: Article

References (60)

1. Khan O., La Thangue N. B., Drug Insight: Histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nature Clinical Practice Oncology 2008 5 12 714 726 10.1038/ncponc1238 2-s2.0-57049120498
2. Song J., Noh J. H., Lee J. H., Eun J. W., Ahn Y. M., Kim S. Y., Hyung Lee S., Park W. S., Yoo N. J., Lee J. Y., Nam S. W., Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005 113 4 264 268 10.1111/j.1600-0463.2005.apm-04.x 2-s2.0-21044447215
3. Krusche C. A., Wülfing P., Kersting C., Vloet A., Böcker W., Kiesel L., Beier H. M., Alfer J., Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Research and Treatment 2005 90 1 15 23 10.1007/s10549-004-1668-2 2-s2.0-16844385708
4. Spurling C. C., Godman C. A., Noonan E. J., Rasmussen T. P., Rosenberg D. W., Giardina C., HDAC3 overexpression and colon cancer cell proliferation and differentiation. Molecular Carcinogenesis 2008 47 2 137 147 10.1002/mc.20373 2-s2.0-38949148986
5. Wu W.-S., Vallian S., Seto E., Yang W.-M., Edmondson D., Roth S., Chang K.-S., The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Molecular and Cellular Biology 2001 21 7 2259 2268 10.1128/MCB.21.7.2259-2268.2001 2-s2.0-0035099686
6. Ferrara F. F., Fazi F., Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P. G., Lo Coco F., Nervi C., Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Research 2001 61 1 2 7 2-s2.0-0035132140
7. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., Duvic M., Kerr D. J., La Thangue N. B., HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proceedings of the National Academy of Sciences of the United States of America 2010 107 14 6532 6537 10.1073/pnas.0913912107 2-s2.0-77950877402
8. Grant S., Easley C., Kirkpatrick P., Vorinostat. Nature Reviews Drug Discovery 2007 6 1 21 22 10.1038/nrd2227 2-s2.0-33845897616
9. Richon V. M., Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics 2010 2 3 457 465 10.2217/epi.10.20 2-s2.0-77954100842
10. Lindemann R. K., Newbold A., Whitecross K. F., Cluse L. A., Frew A. J., Ellis L., Williams S., Wiegmans A. P., Dear A. E., Scott C. L., Pellegrini M., Wei A., Richon V. M., Marks P. A., Lowe S. W., Smyth M. J., Johnstone R. W., Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2007 104 19 8071 8076 10.1073/pnas.0702294104 2-s2.0-34249941680
11. Insinga A., Monestiroli S., Ronzoni S., Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine 2005 11 1 71 76
12. Park J.-H., Jong H.-S., Kim S. G., Jung Y., Lee K.-W., Lee J.-H., Kim D.-K., Bang Y.-J., Kim T.-Y., Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. Journal of Molecular Medicine 2008 86 1 117 128 10.1007/s00109-007-0260-8 2-s2.0-38149093282
13. Bolden J. E., Shi W., Jankowski K., Kan C.-Y., Cluse L., Martin B. P., MacKenzie K. L., Smyth G. K., Johnstone R. W., HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death and Disease 2013 4, article e519 10.1038/cddis.2013.9 2-s2.0-84875978060
14. Ashburner M., Ball C. A., Blake J. A., Botstein D., Butler H., Cherry J. M., Davis A. P., Dolinski K., Dwight S. S., Eppig J. T., Harris M. A., Hill D. P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J. C., Richardson J. E., Ringwald M., Rubin G. M., Sherlock G., Gene ontology: tool for the unification of biology. Nature Genetics 2000 25 1 25 29 10.1038/75556 2-s2.0-0034069495
15. Huang D. W., Sherman B. T., Lempicki R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 2009 4 1 44 57 10.1038/nprot.2008.211 2-s2.0-61449172037
16. Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., Paulovich A., Pomeroy S. L., Golub T. R., Lander E. S., Mesirov J. P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005 102 43 15545 15550 10.1073/pnas.0506580102 2-s2.0-27344435774
17. Ogata H., Goto S., Sato K., Fujibuchi W., Bono H., Kanehisa M., KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Research 1999 27 1 29 34 10.1093/nar/27.1.29 2-s2.0-0032919364
18. Nishimura D., BioCarta. Biotech Software & Internet Report 2001 2 3 117 120 10.1089/152791601750294344
19. Ernst J., Bar-Joseph Z., STEM: a tool for the analysis of short time series gene expression data. BMC Bioinformatics 2006 7, article 191 10.1186/1471-2105-7-191 2-s2.0-33646344978
20. Liberzon A., Subramanian A., Pinchback R., Thorvaldsdóttir H., Tamayo P., Mesirov J. P., Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011 27 12 1739 1740 10.1093/bioinformatics/btr260 2-s2.0-79958135926
21. Huang R., Wallqvist A., Thanki N., Covell D. G., Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics Journal 2005 5 6 381 399 10.1038/sj.tpj.6500331 2-s2.0-33644669581
22. Huang R., Wallqvist A., Covell D. G., Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen. Genomics 2006 87 3 315 328 10.1016/j.ygeno.2005.11.011 2-s2.0-32244434299
23. Huang R., Wallqvist A., Covell D. G., Targeting changes in cancer: assessing pathway stability by comparing pathway gene expression coherence levels in tumor and normal tissues. Molecular Cancer Therapeutics 2006 5 9 2417 2427 10.1158/1535-7163.MCT-06-0239 2-s2.0-33749557850
24. Ernst J., Nau G. J., Bar-Joseph Z., Clustering short time series gene expression data. Bioinformatics 2005 21 1 i159 i168 10.1093/bioinformatics/bti1022 2-s2.0-28644452470
25. Salomonis N., Hanspers K., Zambon A. C., Vranizan K., Lawlor S. C., Dahlquist K. D., Doniger S. W., Stuart J., Conklin B. R., Pico A. R., GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics 2007 8, article 217 10.1186/1471-2105-8-217 2-s2.0-34447640967
26. Doniger S. W., Salomonis N., Dahlquist K. D., Vranizan K., Lawlor S. C., Conklin B. R., MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biology 2003 4, article R7 10.1186/gb-2003-4-1-r7 2-s2.0-0037263812
27. Grayson D. R., Kundakovic M., Sharma R. P., Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Molecular Pharmacology 2010 77 2 126 135 10.1124/mol.109.061333 2-s2.0-74549200467
28. Bakkenist C. J., Kastan M. B., DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003 421 6922 499 506 10.1038/nature01368 2-s2.0-0037472924
29. Groselj B., Sharma N. L., Hamdy F. C., Kerr M., Kiltie A. E., Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. British Journal of Cancer 2013 108 4 748 754 10.1038/bjc.2013.21 2-s2.0-84875223519
30. Robert C., Rassool F. V., HDAC inhibitors: roles of DNA damage and repair. Advances in Cancer Research 2012 116 87 129 10.1016/B978-0-12-394387-3.00003-3 2-s2.0-84867801148
31. Loewer A., Karanam K., Mock C., Lahav G., The p53 response in single cells is linearly correlated to the number of DNA breaks without a distinct threshold. BMC Biology 2013 11, article 114 10.1186/1741-7007-11-114 2-s2.0-84887697240
32. Mirzayans R., Andrais B., Scott A., Murray D., New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. Journal of Biomedicine and Biotechnology 2012 2012 16 170325 10.1155/2012/170325 2-s2.0-84864926277
33. Cao B., Li J., Zhu J., Shen M., Han K., Zhang Z., Yu Y., Wang Y., Wu D., Chen S., Sun A., Tang X., Zhao Y., Qiao C., Hou T., Mao X., The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. The Journal of Biological Chemistry 2013 288 47 34181 34189 10.1074/jbc.M113.472563 2-s2.0-84888329493
34. Wu S., Liu B., Zhang Q., Liu J., Zhou W., Wang C., Li M., Bao S., Zhu R., Dihydromyricetin reduced bcl-2 expression via p53 in human hepatoma HepG2 cells. PLoS ONE 2013 8 11 e76886 10.1371/journal.pone.0076886 2-s2.0-84892428852
35. Aoyama I., Yaegaki K., Calenic B., Ii H., Ishkitiev N., Imai T., The role of p53 in an apoptotic process caused by an oral malodorous compound in periodontal tissues: a review. Journal of Breath Research 2012 6 1 017104 10.1088/1752-7155/6/1/017104 2-s2.0-84857545940
36. Khan O., la Thangue N. B., HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology and Cell Biology 2012 90 1 85 94 10.1038/icb.2011.100 2-s2.0-84855471990
37. Rikiishi H., Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. Journal of Biomedicine and Biotechnology 2011 2011 9 830260 10.1155/2011/830260 2-s2.0-79959344464
38. Akada H., Akada S., Gajra A., Bair A., Graziano S., Hutchison R. E., Mohi G., Efficacy of vorinostat in a murine model of polycythemia vera. Blood 2012 119 16 3779 3789 10.1182/blood-2011-02-336743 2-s2.0-84860316991
39. Glaser K. B., Staver M. J., Waring J. F., Stender J., Ulrich R. G., Davidsen S. K., Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Molecular Cancer Therapeutics 2003 2 2 151 163 2-s2.0-0042905956
40. New M., Olzscha H., la Thangue N. B., HDAC inhibitor-based therapies: can we interpret the code? Molecular Oncology 2012 6 6 637 656 10.1016/j.molonc.2012.09.003 2-s2.0-84869869682
41. Broustas C. G., Lieberman H. B., DNA damage response genes and the development of cancer metastasis. Radiation Research 2014 181 2 111 130 10.1667/RR13515.1 2-s2.0-84896272979
42. Nielsen I., Bentsen I. B., Andersen A. H., Gasser S. M., Bjergbaek L., A Rad53 independent function of Rad9 becomes crucial for genome maintenance in the absence of the RecQ helicase Sgs1. PLoS ONE 2013 8 11 e81015 10.1371/journal.pone.0081015 2-s2.0-84894234636
43. Nasuno T., Mimaki S., Okamoto M., Esumi H., Tsuchihara K., Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Science 2014 105 2 202 210 10.1111/cas.12322 2-s2.0-84893721884
44. Li M., Yu X., Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 2013 23 5 693 704 10.1016/j.ccr.2013.03.025 2-s2.0-84877823968
45. Heideker J., Lis E. T., Romesberg F. E., Phosphatases, DNA damage checkpoints and checkpoint deactivation. Cell Cycle 2007 6 24 3058 3064 10.4161/cc.6.24.5100 2-s2.0-38149030719
46. Rashid M. U., Muhammad N., Faisal S., Amin A., Hamann U., Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan. BMC Cancer 2013 13, article 312 10.1186/1471-2407-13-312 2-s2.0-84879435788
47. Karim S., Mirza Z., Naseer M. I., Al-Qahtani M. H., Ali A., Clinicopathological characteristics and chronology of p53 expression in the development of gastric cancer. Hepato-Gastroenterology 2013 60 128 2113 2118 10.5754/hge12158 2-s2.0-84893647299
48. Koundrioukoff S., Carignon S., Técher H., Letessier A., Brison O., Debatisse M., Stepwise activation of the ATR signaling pathway upon increasing replication stress impacts fragile site integrity. PLoS Genetics 2013 9 7 e1003643 10.1371/journal.pgen.1003643 2-s2.0-84880784164
49. Morita A., Tanimoto K., Murakami T., Morinaga T., Hosoi Y., Mitochondria are required for ATM activation by extranuclear oxidative stress in cultured human hepatoblastoma cell line Hep G2 cells. Biochemical and Biophysical Research Communications 2014 443 4 1286 1290 10.1016/j.bbrc.2013.12.139 2-s2.0-84893725571
50. Kotsinas A., Papanagnou P., Galanos P., Schramek D., Townsend P., Penninger J. M., Bartek J., Gorgoulis V. G., MKK7 and ARF: new players in the DNA damage response scenery. Cell Cycle 2014 13 8 1227 1236 10.4161/cc.28654 2-s2.0-84899066730
51. Genovés J., Alameda F., Mancebo G., Solé J. M., Bellosillo B., Lloveras B., Agramunt S., Baró M. T., Muset M., Casado B., Serrano L., Miralpeix E., Carreras R., Human papillomavirus detection and p16INK4a expression in cervical lesions: a comparative study. Human Pathology 2014 45 4 826 833 10.1016/j.humpath.2013.10.035 2-s2.0-84896526630
52. Mikawa T., Maruyama T., Okamoto K., Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. The Journal of Cell Biology 2014 204 729 745
53. Payton M., Scully S., Chung G., Coats S., Deregulation of Cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene 2002 21 55 8529 8534 10.1038/sj.onc.1206035 2-s2.0-0037028213
54. Karst A. M., Jones P. M., Vena N., Ligon A. H., Liu J. F., Hirsch M. S., Etemadmoghadam D., Bowtell D. D. L., Drapkin R., Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Research 2014 74 4 1141 1152 10.1158/0008-5472.CAN-13-2247 2-s2.0-84894267929
55. Tyson J. J., Novak B., Regulation of the eukaryotic cell cycle: molecular antagonism, hysteresis, and irreversible transitions. Journal of Theoretical Biology 2001 210 2 249 263 10.1006/jtbi.2001.2293 2-s2.0-0035926571
56. Shiozaki A., Nakashima S., Ichikawa D., Fujiwara H., Konishi H., Komatsu S., Kubota T., Okamoto K., Iitaka D., Shimizu H., Nako Y., Takemoto K., Kishimoto M., Otsuji E., Prognostic significance of p21 expression in patients with esophageal squamous cell carcinoma. Anticancer Research 2013 33 10 4329 4335 2-s2.0-84891360246
57. Aoyagi K., Kouhuji K., Miyagi M., Imaizumi T., Kizaki J., Isobe T., Shirouzu K., Expression of p27Kip1 protein in gastric carcinoma. Hepato-Gastroenterology 2013 60 121 390 394 2-s2.0-84877744387
58. Ma X., Gao Y., Fan Y., Ni D., Zhang Y., Chen W., Zhang P., Song E., Huang Q., Ai Q., Li H., Wang B., Zheng T., Shi T., Zhang X., Overexpression of E2F1 promotes tumor malignancy and correlates with TNM stages in clear cell renal cell carcinoma. PLoS ONE 2013 8 9 e73436 10.1371/journal.pone.0073436 2-s2.0-84883328856
59. Massip A., Arcondéguy T., Touriol C., Basset C., Prats H., Lacazette E., E2F1 activates p53 transcription through its distal site and participates in apoptosis induction in HPV-positive cells. FEBS Letters 2013 587 19 3188 3194 10.1016/j.febslet.2013.08.009 2-s2.0-84884291789
60. Thompson R. C., Vardinogiannis I., Gilmore T. D., The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS ONE 2013 8 5 e62822 10.1371/journal.pone.0062822 2-s2.0-84877117327